Sai Life Sciences Q2 FY26 PAT doubles on strong revenue growth

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹924.00

prior close

₹922.30

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%-5.6% vs market

Pharmaceuticals peers, median of 156sector-0.0%-5.8% vs sector

On the reaction day the stock moved 5.6 pts less than Nifty Smallcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.9

10m

-3.4

15m

-2.8

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9-0.2-5.6-0.0-5.8

Next day

-1.5-0.2-1.3-0.7-0.9

-3.7-0.4-3.3-0.9-2.8

-3.2+0.3-3.6+0.1-3.4

-5.6-0.1-5.5+0.2-5.8

-5.7+0.1-5.8+0.0-5.7

-6.4-0.2-6.2-0.3-6.1

15d

-4.5-1.9-2.6-1.6-2.9

-7.1-5.5-1.6-5.3-1.9

+4.5-1.4+6.0-2.9+7.4

-3.4-4.6+1.3-7.4+4.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences reported strong Q2 FY26 results. Consolidated revenue rose about 36% YoY to Rs 537 crore, while profit after tax jumped about 102% to Rs 84 crore. Half-yearly revenue grew about 53% to Rs 1,034 crore with PAT surging over 4x to Rs 144 crore. Operating cash flow remained positive at Rs 93 crore. Auditor Deloitte gave an unmodified review.

Likely market impact

Strong YoY growth in revenue and profit with expanding margins, positive operating cash flow, and a clean auditor review signal robust business momentum for shareholders.